Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
80%(4 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_3
2
33%
Ph phase_4
1
17%
Ph not_applicable
2
33%
Ph phase_2
1
17%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
1(16.7%)
N/ANon-phased studies
2(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (16.7%)
Phase 32 (33.3%)
Phase 41 (16.7%)
N/A2 (33.3%)

Trials by Status

terminated117%
completed583%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_3

Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

NCT02478398
completedphase_3

AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis

NCT02161146
completednot_applicable

Effect of Olopatadine on Allergic Tear Mediators

NCT00609128
completednot_applicable

Olopatadine Eye Drops and Allergy Skin Testing

NCT00775658
terminatedphase_2

A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.

NCT01287338
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02478398Phase 3

Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

Completed
NCT02161146Phase 3

AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis

Completed
NCT00609128Not Applicable

Effect of Olopatadine on Allergic Tear Mediators

Completed
NCT00775658Not Applicable

Olopatadine Eye Drops and Allergy Skin Testing

Completed
NCT01287338Phase 2

A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.

Terminated
NCT00655109Phase 4

A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6